Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Neoplasms 1Leukemia 1Immunologic Deficiency Syndromes 1Hemoglobinopathies 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Photopheresis × Clear all
NCT00179790 2017-03-06

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Completed
22 enrolled
Other hematologic neoplasm

Hemoglobinopathies, Immunologic Deficiency Syndromes, Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡